Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 22Thoracic 19Gastrointestinal 18Sarcoma 14Genitourinary 12CNS 12Breast 10Tumor-Agnostic 6Other solid neoplasm 6Other hematologic neoplasm 5Dermatologic 5Head & Neck 3Lymphoid 2Plasma cell 1Endocrine 1

Conditions

Tongue Neoplasms 1Thyroid cancer, Hurthle cell 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Lymphoid Interstitial Pneumonia 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × cediranib × Head & Neck × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT00458978 2015-05-05

Cediranib Maleate in Treating Patients With Recurrent or Newly Diagnosed Metastatic Head and Neck Cancer

National Cancer Institute (NCI)

Phase 2 Completed
6 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT00243347 2013-10-17

The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer

AstraZeneca

Phase 1 Completed
19 enrolled 7 charts
Head & NeckThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡